Cargando…

Pronounced antibody elevation after SARS‐CoV‐2 BNT162b2 mRNA booster vaccination in nursing home residents

BACKGROUND: Infection control during COVID‐19 outbreaks in nursing facilities is a critical public health issue. Antibody responses before and after the third (booster) dose of SARS‐CoV‐2 vaccination in nursing home residents have not been fully characterized. METHODS: This study included 117 indivi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chong, Yong, Goto, Takeyuki, Tani, Naoki, Yonekawa, Akiko, Ikematsu, Hideyuki, Shimono, Nobuyuki, Tanaka, Yosuke, Akashi, Koichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9530588/ https://www.ncbi.nlm.nih.gov/pubmed/35962568 http://dx.doi.org/10.1111/irv.13030

Ejemplares similares

Contrasting specific antibody response to BNT162b2 mRNA vaccination in SARS-CoV-2-naive and previously infected nursing home residents
por: Chong, Yong, et al.
Publicado: (2022)

Achievement of sufficient antibody response after a fourth dose of wild‐type SARS‐CoV‐2 mRNA vaccine in nursing home residents
por: Chong, Yong, et al.
Publicado: (2023)

No significant influence of pre-vaccination antipyretic use on specific antibody response to a BNT162b2 vaccine booster against COVID-19
por: Tani, Naoki, et al.
Publicado: (2022)

Correlation of Postvaccination Fever With Specific Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 BNT162b2 Booster and No Significant Influence of Antipyretic Medication
por: Tani, Naoki, et al.
Publicado: (2022)

Relation of fever intensity and antipyretic use with specific antibody response after two doses of the BNT162b2 mRNA vaccine
por: Tani, Naoki, et al.
Publicado: (2022)

Post-vaccination antibody evaluation for nosocomial SARS-CoV-2 delta variant breakthrough infection
por: Goto, Takeyuki, et al.
Publicado: (2022)

Genetic testing and serological screening for SARS-CoV-2 infection in a COVID-19 outbreak in a nursing facility in Japan
por: Chong, Yong, et al.
Publicado: (2021)

Clinical significance of SARS‐CoV‐2‐specific IgG detection with a rapid antibody kit for COVID‐19 patients
por: Chong, Yong, et al.
Publicado: (2020)

Dynamics of anti-Spike IgG antibody level after the second BNT162b2 COVID-19 vaccination in health care workers
por: Ikezaki, Hiroaki, et al.
Publicado: (2022)

Dynamics of anti-spike IgG antibody after a third BNT162b2 COVID-19 vaccination in Japanese health care workers
por: Ikezaki, Hiroaki, et al.
Publicado: (2022)

BNT162b2 Vaccine Booster and Mortality Due to Covid-19
por: Arbel, Ronen, et al.
Publicado: (2021)

Frosted branch angiitis after booster vaccination with BNT162b2
por: Haas, A.-M., et al.
Publicado: (2023)

Immune Responses After Vaccination With Primary 2-Dose ChAdOx1 Plus a Booster of BNT162b2 or Vaccination With Primary 2-Dose BNT162b2 Plus a Booster of BNT162b2 and the Occurrence of Omicron Breakthrough Infection
por: Choi, Seong-Ho, et al.
Publicado: (2023)

Clinical Significance of COVID-19 and Diabetes: In the Pandemic Situation of SARS-CoV-2 Variants including Omicron (B.1.1.529)
por: Yonekawa, Akiko, et al.
Publicado: (2022)

Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel
por: Bar-On, Yinon M., et al.
Publicado: (2021)

Immunogenicity of a BNT162b2 vaccine booster in health-care workers
por: Saiag, Esther, et al.
Publicado: (2021)

Immunogenicity evaluation after BNT162b2 booster vaccination in healthcare workers
por: Zurac, Sabina, et al.
Publicado: (2022)

Effectiveness of the BNT162b2 and the CoronaVac vaccines and boosters in healthcare workers
por: Çulpan, Hazal Cansu, et al.
Publicado: (2023)

Comparison of Waning Immunity Between Booster Vaccination and 2-Dose Vaccination With BNT162b2
por: Jung, Jiwon, et al.
Publicado: (2022)

Correlates of protection for booster doses of the SARS-CoV-2 vaccine BNT162b2
por: Hertz, Tomer, et al.
Publicado: (2023)

Humoral Response to Pfizer BNT162b2 Vaccine Booster in Maintenance Hemodialysis Patients
por: Shashar, Moshe, et al.
Publicado: (2022)

Protection against Covid-19 by BNT162b2 Booster across Age Groups
por: Bar-On, Yinon M., et al.
Publicado: (2021)

Adverse reactions of BNT162b2 vaccine booster against COVID‐19 in Japan
por: Nishizawa, Toshinori, et al.
Publicado: (2022)

Platypnea-Orthodeoxia Syndrome in Coronavirus Disease 2019 Pneumonia: A Case Report and Literature Review
por: Tanimoto, Takahiko, et al.
Publicado: (2023)

Cost-effectiveness analysis of BNT162b2 COVID-19 booster vaccination in the United States
por: Li, Rui, et al.
Publicado: (2022)

Acute myopericarditis following administration of the BNT162b2 booster vaccine against COVID19
por: Sivan, S.K., et al.
Publicado: (2022)

Mucosal immune response after the booster dose of the BNT162b2 COVID-19 vaccine
por: Azzi, Lorenzo, et al.
Publicado: (2023)

Protection following BNT162b2 booster in adolescents substantially exceeds that of a fresh 2-dose vaccine
por: Amir, Ofra, et al.
Publicado: (2022)

Antibody levels after BNT162b2 vaccine booster and SARS-CoV-2 Omicron infection
por: Vietri, Maria Teresa, et al.
Publicado: (2022)

Effects of BNT162b2 Covid-19 Vaccine Booster in Long-Term Care Facilities in Israel
por: Muhsen, Khitam, et al.
Publicado: (2021)

Response to tozinameran (BNT162b2) booster in twice-vaccinated kidney transplant and maintenance dialysis patients
por: Ben-Dov, Iddo Z., et al.
Publicado: (2022)

Immunogenicity and safety of BNT162b2 mRNA vaccine booster in actively treated patients with cancer
por: Ligumsky, Hagai, et al.
Publicado: (2022)

Serum C reactive protein predicts humoral response after BNT162b2 booster administration
por: Salvagno, Gian Luca, et al.
Publicado: (2022)

Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the Omicron period in Brazil
por: Cerqueira-Silva, Thiago, et al.
Publicado: (2022)

Protective antibodies and T cell responses to Omicron variant after the booster dose of BNT162b2 vaccine
por: Naaber, Paul, et al.
Publicado: (2022)

Functionally impaired antibody response to BNT162b2 booster vaccination in CVID IgG responders
por: Sauerwein, Kai M.T., et al.
Publicado: (2023)

Functional CVIDs phenotype clusters identified by the integration of immune parameters after BNT162b2 boosters
por: Piano Mortari, Eva, et al.
Publicado: (2023)

Humoral and Cellular Immune Response Elicited by the BNT162b2 COVID-19 Vaccine Booster in Elderly
por: Dalla Gasperina, Daniela, et al.
Publicado: (2023)

Heterologous Booster with BNT162b2 Induced High Specific Antibody Levels in CoronaVac Vaccinees
por: Masson, Letícia Carrijo, et al.
Publicado: (2023)

COVID‐19 after BNT162b2 two‐dose primary series does not improve the efficacy of a booster dose in nursing home residents
por: Blain, Hubert, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_s5tpdtvtr2sbuinunac4u8uate